• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vaxcyte, Inc. - Common Stock (NQ:PCVX)

46.05 +0.73 (+1.61%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 795,354
Open 46.05
Bid (Size) 46.05 (100)
Ask (Size) 70.00 (100)
Prev. Close 45.32
Today's Range 45.74 - 47.72
52wk Range 27.66 - 93.77
Shares Outstanding 93,706,790
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Vaxcyte's Chief Technical Ops Officer Sells Shares ↗
January 03, 2026
Focused on next-generation vaccines for bacterial diseases, this biotech just reported a notable insider sale amid a challenging year. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
December 08, 2025
From Vaxcyte, Inc.
Via GlobeNewswire

Performance

YTD
-0.9%
-0.9%
1 Month
+2.9%
+2.9%
3 Month
+9.7%
+9.7%
6 Month
+27.1%
+27.1%
1 Year
-43.2%
-43.2%

More News

Read More
News headline image
These 3 Stocks Are Using Buybacks to Signal Market Confidence ↗
November 18, 2025
Via MarketBeat
News headline image
Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
November 04, 2025
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Thermo Fisher Launches Four-Part Bond Offering Ahead Of Possible Government Shutdown ↗
September 30, 2025
Via Benzinga
Topics Bonds
News headline image
Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services
September 30, 2025
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data ↗
September 11, 2025
Via Benzinga
News headline image
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
September 03, 2025
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
August 07, 2025
Via Benzinga
News headline image
Vaxcyte (PCVX) Q2 Loss Widens 11% ↗
August 06, 2025
Via The Motley Fool
Topics Intellectual Property
News headline image
Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)
August 06, 2025
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
May 07, 2025
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
May 01, 2025
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
April 01, 2025
Via Benzinga
News headline image
Top stock movements in today's session. ↗
March 31, 2025
Via Chartmill
News headline image
Monday's session: top gainers and losers ↗
March 31, 2025
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
March 31, 2025
Via Benzinga
News headline image
These stocks are gapping in today's session ↗
March 31, 2025
Via Chartmill
News headline image
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet ↗
March 31, 2025
Via Benzinga
Topics Stocks
News headline image
Monday's pre-market session: top gainers and losers ↗
March 31, 2025
Via Chartmill
News headline image
Nasdaq Tumbles Over 300 Points; Chicago PMI Rises In March ↗
March 31, 2025
Via Benzinga
News headline image
Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns ↗
March 31, 2025
Via Investor's Business Daily
News headline image
Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine ↗
March 31, 2025
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
March 31, 2025
Via Benzinga
News headline image
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
March 31, 2025
From Vaxcyte, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Vaxcyte, Inc. - Common Stock publicly traded?
Yes, Vaxcyte, Inc. - Common Stock is publicly traded.
What exchange does Vaxcyte, Inc. - Common Stock trade on?
Vaxcyte, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vaxcyte, Inc. - Common Stock?
The ticker symbol for Vaxcyte, Inc. - Common Stock is PCVX on the Nasdaq Stock Market
What is the current price of Vaxcyte, Inc. - Common Stock?
The current price of Vaxcyte, Inc. - Common Stock is 46.05
When was Vaxcyte, Inc. - Common Stock last traded?
The last trade of Vaxcyte, Inc. - Common Stock was at 01/09/26 04:00 PM ET
What is the market capitalization of Vaxcyte, Inc. - Common Stock?
The market capitalization of Vaxcyte, Inc. - Common Stock is 4.32B
How many shares of Vaxcyte, Inc. - Common Stock are outstanding?
Vaxcyte, Inc. - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap